HOPKINTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and inflammatory diseases, today announced that a trial in progress poster will be presented for the Phase 1a/1b trial of the company’s intravenously-administered STING agonist candidate, SB 11285, at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be conducted virtually from May 29-June 2, 2020.
All posters, including poster discussions, will be available on the meeting website beginning Friday, May 29 at 8:00 am ET. A copy of the poster will also be made available on the Publications page of Spring Bank’s website.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleotide platform. The company designs its compounds to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its STING product portfolio with its lead clinical product candidate, SB 11285, an intravenously-administered immunotherapeutic agent for the treatment of selected cancers, its STING antagonist compounds for the treatment of a broad range of inflammatory diseases and its STING agonist ADC program for potential oncology applications. For more information, please visit www.springbankpharm.com.Investors:LifeSci Advisors, LLC
Ashley R. Robinson
(617) 535-7742
[email protected]Media:
McNeil, Gray & Rice
Kristin Nugent
Senior Account Supervisor
(617) 367-0100Source: Spring Bank Pharmaceuticals, Inc. 
Bay Street News